Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor

Bruton tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a major therapeutic target for B-cell–driven malignancies. However, approved covalent BTK inhibitors (cBTKis) are associated with treatment limitations because of off-target side effects, suboptimal oral pharmacology, and development of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez, Eliana B., Ebata, Kevin, Randeria, Hetal S., Rosendahl, Mary S., Cedervall, E. Peder, Morales, Tony H., Hanson, Lauren M., Brown, Nicholas E., Gong, Xueqian, Stephens, Jennifer, Wu, Wenjuan, Lippincott, Isabel, Ku, Karin S., Walgren, Richard A., Abada, Paolo B., Ballard, Joshua A., Allerston, Charles K., Brandhuber, Barbara J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651869/
https://www.ncbi.nlm.nih.gov/pubmed/36796019
http://dx.doi.org/10.1182/blood.2022018674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651869/
https://www.ncbi.nlm.nih.gov/pubmed/36796019
http://dx.doi.org/10.1182/blood.2022018674

Ejemplares similares